NCT02665039View on ClinicalTrials.gov

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Urothelial CarcinomaBladder CancerRenal Pelvis CancerUreter CancerUrethra Cancer
Interventions
DRUG

Vinflunine

"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min"

DRUG

Gemcitabine

Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2

DRUG

Carboplatin

Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5

Trial Locations (2)

DK-2100

Department of Oncology, Rigshospitalet, Copenhagen

Unknown

Department of Oncology, Karolinska University Hospital, Stockholm

All Listed Sponsors
lead

Dr Anders Ullén

OTHER

NCT02665039 - A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function | Biotech Hunter | Biotech Hunter